Buch, Englisch, 327 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 5772 g
ISBN: 978-981-10-9500-9
Verlag: Springer Nature Singapore
Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Pneumologie, Atmung, Asthma
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
Weitere Infos & Material
Part I Diagnosis.- 1 Classification of adenocarcinoma of the lung - with a special reference to prognosis .- 2 Screening lung cancer with low dose CT combined with molecular markers.- 3 PET-CT, bio-imaging for predicting prognosis and response to chemotherapy in patients with lung cancer.- 4 Methods in molecular diagnosis.- 5 Accurate nodal staging and biomarker testing with endobronchial ultrasound-guided transbronchial needle aspiration.- 6 Next generation sequencing and bioinformatics.- 7 Companion Diagnostics.- Part II Treatment.- 8 Small cell lung cancer and molecular targeted therapy.- 9 Locally advanced non-small cell lung cancer and molecular targeted therapy.- 10 EGFR mutant.- 11 ALK mutant.- 12 Minor-driver mutant.- 13 Mechanism of resistance to targeted molecular therapy.- 14 Immunotherapy.- 15 Lung cancer complicated with interstitial lung diseases.- 16 Management of adverse effects by molecular targeted therapy and immunotherapy.- Part III Evaluation.- 17 Health related-quality of life in molecular targeted therapy.- 18 Gene signature.- Part IV Novel approach.- 19 Targeting epithelial-mesenchymal transition and cancer stem cell- 20 Targeting the Lung Cancer Microenvironment: Harnessing Host Responses.